Heart HealthResearch PaperPaywall

One Month of Dual Therapy Then Blood Thinner Alone Looks Feasible After Stenting in High-Bleeding-Risk Patients

In high-bleeding-risk stent patients, moving to anticoagulant alone after one month showed low clot and bleeding events in a POEM trial sub-analysis.

Wednesday, November 18, 2026 1 view
Published in Am Heart J
cardiac catheterization lab with interventional cardiologist at a fluoroscopy monitor during a coronary stent procedure

Summary

Many older heart patients who get a coronary stent also take a blood thinner for another condition, such as atrial fibrillation. They are often at high risk of bleeding, so doctors want to cut the number of drugs they take as early as possible. This sub-analysis of the POEM trial looked at 439 high-bleeding-risk patients who received a bioresorbable-polymer drug-eluting stent. Patients without a blood-thinner need (281) took two antiplatelet drugs for one month, then one. Patients who needed an anticoagulant (158) took it with one antiplatelet drug for one month, then the anticoagulant alone. At one year, the combined rate of cardiac death, heart attack or stent clot was 2.6% in the anticoagulant group and 6.1% in the other group, a difference that was not statistically significant. Serious bleeding was uncommon in both groups (1.3% vs 2.6%). The groups were not randomized against each other, so this supports further testing rather than a change in practice.

0:00--:--

Detailed Summary

Why this matters: Heart disease is a leading limiter of healthspan, and the patients most likely to need coronary stents are often older and frail. Many also take an oral anticoagulant for conditions like atrial fibrillation. Every added antithrombotic drug raises bleeding risk, so the best way to shorten therapy in this group is an open question.

What was studied: This was a prespecified sub-analysis of the POEM trial, which enrolled high-bleeding-risk patients treated with a bioresorbable-polymer everolimus-eluting stent. Patients were stratified by whether they needed an oral anticoagulant. The non-OAC group (n=281) received one month of dual antiplatelet therapy followed by a single antiplatelet drug. The OAC group (n=158) received one month of an anticoagulant plus a P2Y12 inhibitor, followed by anticoagulant monotherapy.

Key results: At one year, the primary endpoint (cardiac death, myocardial infarction, or definite/probable stent thrombosis) occurred in 6.1% of the non-OAC group and 2.6% of the OAC group (HR 0.41, 95% CI 0.14-1.22; P=.097), which is not a significant difference. Secondary ischemic outcomes were similar. Major BARC type 3-5 bleeding was infrequent: 2.6% versus 1.3% (P=.369). A per-protocol analysis excluding patients with dual antiplatelet therapy beyond one month gave consistent results.

Implications: Dropping to anticoagulant alone at one month was associated with low ischemic and bleeding event rates, comparable to single antiplatelet therapy in the other group. The authors conclude that early anticoagulant monotherapy is a feasible strategy that deserves randomized testing.

Caveats: The comparison is between two different patient populations treated with different regimens, not a randomized comparison, and the groups differ in baseline characteristics. Event counts were small, confidence intervals were wide, and the study was not designed to prove equivalence. This summary is based on the abstract only.

Key Findings

  • One-year primary endpoint (cardiac death, MI, stent thrombosis): 2.6% with early OAC monotherapy vs 6.1% in non-OAC group; not significant (P=.097).
  • Major bleeding (BARC 3-5) was infrequent: 1.3% in the OAC group vs 2.6% in the non-OAC group (P=.369).
  • Secondary ischemic outcomes were similar between the groups.
  • Per-protocol analysis excluding dual antiplatelet therapy beyond one month gave consistent results.
  • The authors call for randomized trials; this analysis is hypothesis-generating, not practice-changing.

Methodology

Prespecified sub-analysis of the POEM trial in high-bleeding-risk patients receiving a bioresorbable-polymer everolimus-eluting stent (n=439). Patients were stratified by OAC indication into non-OAC (n=281) and OAC (n=158) groups, each with a one-month antithrombotic regimen. Outcomes were analyzed by log-rank test and Cox regression, intention-to-treat, with a per-protocol sensitivity analysis.

Study Limitations

The comparison is between non-randomized groups with different indications, and event numbers were small with wide confidence intervals, so no equivalence or superiority can be claimed. Follow-up was one year, and the study used one specific stent type. This summary is based on the abstract only.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: